Interstitial Lung Disease
Conditions
Keywords
ILD
Brief summary
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Detailed description
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.
Interventions
OTHERILD
100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
OTHERHealthy
100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
OTHERPneumonia
100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Sponsors
Mayo Clinic
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia * Patients willing to provide written informed consent
Exclusion criteria
* Unwillingness/unable to give blood samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Future Disease Management | 1 visit | Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease. |
Countries
United States
Contacts
CONTACTMichael Stachowitz
PRINCIPAL_INVESTIGATOREva M Carmona Porquera, MD, PhD
Mayo Clinic
Outcome results
None listed